Biogen Inc. (BIIB)

242.51
NASDAQ
Prev Close 243.38
Day Low/High 240.07 / 244.86
52 Wk Low/High 223.25 / 374.99
Exchange NASDAQ
Shares Outstanding 153.88B
Market Cap 37.45B
P/E Ratio 8.03
Div & Yield N.A. (N.A)
Biogen Is Set for a Tradable Rally

Biogen Is Set for a Tradable Rally

BIIB looks like it can rally at least 10% from here.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Biogen Is In a Downtrend With Further Risk Ahead

Biogen Is In a Downtrend With Further Risk Ahead

Charts are signalling more trouble ahead for the stock.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

The challenge of this market is to keep finding new buy entries as more and more stocks become extended.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

M&A Rumors Rise Again

About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes Jumps on License Deal With Biogen -- Biotech Movers

Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

Biogen Is a new 'Hold' at Canaccord

Closing Bell: Stocks Surge on Strong Earnings Reports Across the Board

Closing Bell: Stocks Surge on Strong Earnings Reports Across the Board

Stocks closed confidently higher Tuesday.

Caterpillar, McDonald's and 3M Earnings Fuel Stock Rebound

Caterpillar, McDonald's and 3M Earnings Fuel Stock Rebound

Strong earnings from Dow components Caterpillar, McDonald's and 3M were on track to push the blue-chip index higher after a 0.23% decline on Monday.

Biogen Raised to Buy at Stifel

Biogen Shoots for More Upside

Biogen Shoots for More Upside

We like this name for higher prices into year-end.

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'

RBC Starts Biogen at Sector Perform

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Today's breakout move in the stock is a highlight of the surging sector.

Biogen Raised to Buy at Goldman

Closing Bell: S&P 500 at Record; Senate Passes Motion to Proceed on Healthcare

Closing Bell: S&P 500 at Record; Senate Passes Motion to Proceed on Healthcare

The S&P 500 and Nasdaq end at records.

4 Stocks Warren Buffett Would Love

4 Stocks Warren Buffett Would Love

These disparate names seem to fit quite well with the investment approach of the Oracle of Omaha.

The Dow Binges on Earnings

The Dow Binges on Earnings

Get ready for another heavy earnings slate

Biogen Ready for a Big Bounce

Biogen Ready for a Big Bounce

The chart shows this stock has bottomed.